Citi Pharma Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0126201018
PKR
85.11
-1.37 (-1.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Hoechst Pakistan Ltd.
Otsuka Pakistan Ltd.
Abbott Laboratories (Pakistan) Ltd.
Haleon Pakistan Ltd.
Highnoon Laboratories Ltd.
GlaxoSmithKline Pakistan Ltd.
AGP Ltd.
Ferozsons Laboratories Ltd.
Macter International Ltd.
The Searle Co. Ltd.
Citi Pharma Ltd.
Why is Citi Pharma Ltd. ?
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.63
2
Healthy long term growth as Net Sales has grown by an annual rate of 280.07% and Operating profit at 191.98%
3
Flat results in Mar 25
  • OPERATING CASH FLOW(Y) Lowest at PKR -913.66 MM
  • INTEREST(Q) At PKR 99.06 MM has Grown at 45.96%
  • DEBT-EQUITY RATIO (HY) Highest at 29.09 %
4
With ROE of 14.9, it has a attractive valuation with a 3.5 Price to Book Value
  • Over the past year, while the stock has generated a return of 0%, its profits have risen by 3.1% ; the PEG ratio of the company is 7.7
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Citi Pharma Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Citi Pharma Ltd.
-100.0%
3.85
56.83%
Pakistan KSE 100 Share
60.28%
2.81
22.77%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
59.49%
EBIT Growth (5y)
78.07%
EBIT to Interest (avg)
8.63
Debt to EBITDA (avg)
0.27
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
1.62
Tax Ratio
30.09%
Dividend Payout Ratio
89.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.56%
ROE (avg)
13.90%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
1.95
EV to EBIT
14.04
EV to EBITDA
12.71
EV to Capital Employed
1.85
EV to Sales
1.71
PEG Ratio
3.39
Dividend Yield
NA
ROCE (Latest)
13.19%
ROE (Latest)
8.21%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -11.27% (YoY

OPERATING PROFIT MARGIN(Q)

Highest at 13.53 %

-7What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at PKR -913.66 MM

INTEREST(Q)

At PKR 99.06 MM has Grown at 45.96%

DEBT-EQUITY RATIO (HY)

Highest at 29.09 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 3.34%

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.84%

Here's what is working for Citi Pharma Ltd.
Operating Profit Margin
Highest at 13.53 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Raw Material Cost
Fallen by -11.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at PKR 56.62 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (PKR MM)

Depreciation
At PKR 56.62 MM has Grown at 162.52%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (PKR MM)

Here's what is not working for Citi Pharma Ltd.
Interest
At PKR 99.06 MM has Grown at 45.96%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (PKR MM)

Operating Cash Flow
Lowest at PKR -913.66 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (PKR MM)

Debt-Equity Ratio
Highest at 29.09 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio
Lowest at 3.34%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 4.84%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio